Section snippets Author’s contributionsDA, Initial draft, revision, and editing, KA, Data acquisition and editing, GNR, Final approval Financial support and sponsorshipNone Declaration of Competing InterestNothing to report

Section snippets Authors' contributions:All authors were responsible for the study concept, data acquisition and analysis, the integrity of the data and the accuracy of the data analysis, the drafting, and the critical revision of the manuscript for important intellectual content, and approved the final version of the article. Terry Yip is the submission’s guarantor of the article. Financial support:None

BackgroundApproximately half of patients with Crohn's disease require ileocolonic resection. Of these, 50% will subsequently have endoscopic disease recurrence within 1 year. We aimed to evaluate the efficacy and safety of vedolizumab to prevent postoperative recurrence of Crohn's disease. MethodsREPREVIO was a double-blind, randomised, placebo-controlled trial conducted at 13 academic or teaching

No Abstract

Section snippets Limitations in ctDNA DetectionThe study reports a concordance sensitivity of 84.8% for ctDNA when compared with tissue-based genomic profiling. While promising, this sensitivity indicates that certain actionable mutations present in tissue samples may not be detected by ctDNA alone, raising concerns about its efficacy as a standalone diagnostic approach. Evidence from other studies

Section snippets Author’s contributionsPeng Luo : Study design & Manuscript Writing.Anqi Lin and Kai Miao : Study design & Manuscript Revision. Declaration of Competing InterestWe declare there is no any conflict of interest. Acknowledgements & FundingNone

To define the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and identify therapeutic options, it is crucial to understand the sources of hepatic fat accumulation. In patients with MASLD, it is estimated that hepatic triglycerides are primarily derived from adipose tissue as free fatty acids (~59%), followed by de novo lipogenesis (~26%) and diet (~15%). However

Liver transplantation is associated with a high risk of postoperative complications due to the complexity of the surgical procedure, recipient disease severity and wide range of graft quality which remains somewhat unpredictable. However, survival rates after transplantation continue to improve and the focus has thus turned to other clinically relevant endpoints including posttransplant complications

Section snippets Authors ContributionsAM drafted the letter. All authors (AM, MRP and ET) contributed equally to the study concept, reviewed and approved the final version of letter. Financial SupportNilGEMA-Na: a crucial step in solving to the MELD-Creatinine dilemmaWe read with great interest the study by Dr Rosenstengle and colleagues examining MELD subtypes and the effect on intention-to-treat

Section snippets AcknowledgementsA.M. is supported by a personal ZONMW-VENI grant 2023 (09150162310148)

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Section snippets Low-to-moderate alcohol consumption is associated with increased fibrosis in MASLDMarti-Aguado, Calleja and coworkers attempted to evaluate the prevalence and impact of different levels of alcohol consumption on the severity of metabolic dysfunction-associated steatotic liver disease (MASLD). The authors found that obesity, diabetes and alcohol consumption were independently associated

No Abstract

No Abstract

Section snippets DescriptionA 74-year-old male was admitted to our hospital with subtle jaundice and weight loss. His medical history included ulcerative colitis, well-controlled with mesalazine, and HCV infection successfully treated with direct-acting antivirals 2 years prior. Last liver stiffness measurement was 4.4 kPa. Laboratory tests showed a normal hemogram, moderate elevation of aminotransferases

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/locate/withdrawalpolicy).

Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide disease with a broad spectrum of symptoms. Though being mild at early stages, further development of MASLD causes steatohepatitis, cirrhosis, liver cancers and accompanied diabetes. Discovery of the critical regulators in MASLD progression hold great values in both basic and translational medicine.

No Abstract

Section snippets Authors’ contributionsCAP designed the study and wrote the manuscript, AHT and AL acquired, compiled, and analysed the data, JM and RV finalized the manuscript and made critical revisions, all authors accepted the final version of manuscript for submission. Financial supportThe authors received no financial support to produce this manuscript. Declaration of Competing InterestThe authors

Section snippets Authors contributionsQin Guo: Conceptualization, Writing – original draft; Hui Li: Conceptualization, Funding acquisition, Writing – review & editing; Chengshan Guo: Funding acquisition, Writing – review & editing. Financial support statementThis work was supported by the Medical and Health Research Project of Baoan District (No. 2023JD250), and the Key Specialties in Clinical Medicine

Section snippets Author contributionsConceptualization, data curation, formal analysis and writing of the manuscript were performed by EV and WL. Financial supportNone. Declaration of Competing InterestWL serves as a consultant for Cook Medical, MRM Health, and CSL Behring, and has received speaker’s fees from Boston Scientific. No other conflicts of interest were withheld. AcknowledgementsWe wish

Section snippets Conflict of interest statementThe authors declare no conflict of interest. Uncited reference[17]; [18]; [19]; [17]; [18]; [19]. Authors' contributionsJGH and NV developed the ideas presented and wrote the manuscript. Financial supportNo particulars to report

Section snippets Financial supportFunded by the National Cancer Institute Intramural Research Program. Declaration of Competing InterestThe authors declare no conflicts of interest that pertain to this work.Please refer to the accompanying ICMJE disclosure forms for further details.Adipose triglyceride lipase (ATGL), encoded by the PNPLA2 gene in humans, hydrolyzes triacylglycerols to diacylglycerols

Cutting-edge research has expanded our understanding of the macrophage activation programs in liver diseases making this immune cell type a therapeutic target. Clinical data on macrophage infiltration and polarization states have been used to help predict mortality or poor prognosis in patients with liver cirrhosis and/or hepatocellular carcinoma. The latest single-cell and spatial transcriptomics

Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis. Primarily affecting middle-aged women, the diagnosis of PBC is typically straightforward with most patients presenting with cholestatic liver tests and the highly specific anti-mitochondrial antibody. For decades

Hepatocellular carcinoma (HCC) is characterized by metabolic pathway aberrations, which enable cancer cells to meet their energy demands and accelerate malignant progression. Identifying novel metabolic players governing therapy resistance and self-renewal in HCC is crucial, as these properties are likely responsible for tumor recurrence. Clinical traits and RNA-seq of HCC patients in TCGA were used

BackgroundLaparoscopic surgery is increasingly used for rectal cancer, but the long-term oncological outcomes for low rectal cancer have not been fully established. We aimed to evaluate the 3-year survival outcomes of laparoscopic surgery versus open surgery in the treatment of low rectal cancer. MethodsThis multicentre, randomised, controlled, non-inferiority trial was conducted at 22 tertiary hospitals

No Abstract

Section snippets Financial suppportThe research of the authors is supported in part by grants from the German Federal Ministry of Health (BMG), the Ministry of Culture and Science of the State North Rhine Westphalia (MKW NRW) to DDZ, and the German Federal Ministry of Education and Research (BMBF) and the MKW NRW to German Center for Diabetes Research (DZD e. V.). The research of M.R. is supported

Section snippets Author contributionsconcept and design: DS, AZ, FS; drafted the letter: DS, AZ, FS. All authors approved the final version of this letter. Financial supportNo financial support was received for this study. Declaration of Competing InterestFS has received lecture fees and research grant from W.L. Gore, Cook Medical and Echosens.

Section snippets Grant supportThis work was supported by National IT Industry Promotion Agency grant funded by the Korea Ministry of Science and ICT (S0252-21-1001), Liver Research Foundation of Korea as part of Bio Future Strategies Research Project, and Seoul National University Hospital Research Fund (04-2019-3090). Authors’ contributionsMH and JL both drafted and reviewed the letter equally Declaration

Section snippets Author’s contributionsZhigang Wei: Study design & Manuscript Writing.Dan Shan and Chaojie Liang: Study design & Manuscript Revision. Declaration of Competing InterestWe declare there is no any conflict of interest. Acknowledgements & FundingThis work was supported by Shanxi Medical University Doctoral Start-up Fund (XD1802) and Shanxi Scholarship Council of China (20221852).

Section snippets Financial disclosure fundingNo financial support was received for this letter. Funding fundingNone Conflict-of-interest statement COIThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Author contributions author-disclosureHCM: manuscript drafting; YHH: critical expert

Section snippets Author’s contributionBBL prepared the first draft. SA critically reviewed and approved the final manuscript. Financial disclosureNone Declaration of Competing InterestBikrant Bihari Lal and Seema Alam declare no financial or non-financial conflict of interest.